A research team from the Korea Research Institute of Chemical Technology (KRICT) has discovered a novel SRV2 envelope protein that significantly enhances the production efficiency of CAR immune cell therapies. Published on July 1, 2026 in Nature Communications, this breakthrough could revolutionize the manufacturing process of therapies designed to combat cancer.
Understanding CAR Immune Cell Therapies
CAR immune cell therapies are advanced treatments that genetically modify a patient's immune cells, such as T cells or natural killer (NK) cells, enabling them to better recognize and destroy cancer cells. Despite their clinical effectiveness, the production of these therapies is often complex and costly.
The manufacturing process relies heavily on viral vectors that deliver therapeutic genes into immune cells. These vectors must be engineered to eliminate harmful functions while maintaining their gene transfer capabilities. The envelope proteins of these viruses play a crucial role in this process.
Significance of the SRV2 Envelope Protein
The research team, led by Dr. Chi Hoon Park, identified that the newly discovered SRV2 envelope protein exhibits a structure that is highly compatible with the ASCT2 receptor, which is prevalent on T and NK cells. This compatibility facilitates more efficient gene transduction, ultimately improving the therapeutic outcomes of CAR therapies.
Experimental results revealed that SRV2-pseudotyped retroviral vectors achieved viral titers that were substantially higher than those of the traditional RD114 envelope protein. Specifically, CAR-T cells generated using SRV2 vectors displayed a 20%–25% increase in CAR expression compared to those produced via conventional methods.
Promising Results and Future Directions
In animal studies, untreated mice developed tumors within approximately 10 days, while those treated with RD114-based CAR-T cells showed delayed tumor growth. In stark contrast, mice administered with SRV2-based CAR-T cells had significantly improved outcomes, with only one out of four developing tumors.
The research team has optimized the manufacturing process for SRV2-based vectors, including plasmid ratios and production protocols. Plans for follow-up studies are underway, with aims to scale up production and commercialization in the near future. KRICT President Seok Min Shin emphasized the importance of this discovery, stating, "This study is significant because we identified a new candidate envelope protein that outperforms RD114, the gene-delivery key that has been widely used worldwide."
- Discovery of SRV2 envelope protein enhances CAR therapy production.
- Higher viral titers than RD114 envelope protein.
- Improved CAR expression by 20%–25% in CAR-T cells.
- Superior antitumor activity in animal studies.
🤖 This article was rewritten by Feed and Figures' editorial AI from a report originally published by Phys.org. Facts and quotes are preserved from the original; the rewrite focuses on clarity and structure. For the unedited original, see the source link below.
